Test | All | ALND | SLNB | SLBN vs ALND | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Category | N | n (%) | p value* | N | n (%) | N | n (%) | Odd Ratio95%CI | p value** | |
Age in class | <= 40 | 45 | 44(.98) | <.001 | 22 | 21(.95) | 23 | 23(1.0) | > 999[< 0.01,> 999] | 0.978 |
41–75 | 828 | 582(.70) | 376 | 266(.71) | 452 | 316(.70) | 0.96[0.71, 1.30] | 0.794 | ||
> 75 | 53 | 18(.34) | 25 | 10(.40) | 28 | 8(.29) | 0.61[0.19,1.88] | 0.387 | ||
Tumor size (mm) | <=10 | 143 | 64(.45) | 57 | 27(.47) | 86 | 37(.43) | 0.84[0.43,1.64] | 0.610 | |
10–30 | 684 | 506(.74) | 323 | 236(.73) | 361 | 270(.75) | 1.09[0.78,1.54] | 0.608 | ||
> 30 | 96 | 73(.76) | <.001 | 41 | 34(.83) | 55 | 39(.71) | 0.51[0.19,1.37] | 0.179 | |
Histology type | Infiltrant ductal | 748 | 543(.73) | 340 | 246(.72) | 408 | 297(.73) | 1.02[0.74,1.41] | 0.893 | |
Infiltrant lobular | 101 | 50(.50) | 45 | 25(.56) | 56 | 25(.45) | 0.65[0.30,1.42] | 0.279 | ||
Mixed | 25 | 19(.76) | <.001 | 12 | 10(.83) | 13 | 9(.69) | 0.46[0.07,3.05] | 0.425 | |
Other | 52 | 32(.62) | 26 | 16(.62) | 26 | 16(.62) | 1.00[0.33,3.02] | 1.000 | ||
SBR grade | Gr I | 206 | 88(.43) | <.001 | 98 | 40(.41) | 108 | 48(.44) | 1.16[0.67,2.01] | 0.600 |
Gr II | 464 | 317(.68) | 200 | 139(.70) | 264 | 178(.67) | 0.91[0.61,1.35] | 0.635 | ||
Gr III | 237 | 223(.94) | 116 | 110(.95) | 121 | 113(.93) | 0.77[0.26,2.29] | 0.640 | ||
LVI | No | 275 | 235(.85) | <.001 | 130 | 110(.85) | 145 | 125(.86) | 1.14[0.58,2.22] | 0.709 |
Yes | 616 | 394(.64) | 276 | 178(.64) | 340 | 216(.64) | 0.96[0.69,1.34] | 0.805 | ||
Capsular Effraction | No | 673 | 467(.69) | 313 | 217(.69) | 360 | 250(.69) | 1.01[0.72,1.40] | 0.974 | |
Yes | 167 | 122(.73) | 0.355 | 75 | 56(.75) | 92 | 66(.72) | 0.86[0.43,1.72] | 0.673 | |
Hormonal receptors status | Negative | 75 | 73(.97) | <.001 | 39 | 38(.97) | 36 | 35(.97) | 0.92[0.06,15.02] | 0.955 |
Positive | 837 | 568(.68) | 377 | 257(.68) | 460 | 311(.68) | 0.97[0.73,1.30] | 0.863 | ||
HER2 status | Negative | 794 | 532(.67) | 358 | 242(.68) | 436 | 290(.67) | 0.95[0.71,1.28] | 0.747 | |
Positive | 102 | 98(.96) | <.001 | 52 | 50(.96) | 50 | 48(.96) | 0.96[0.13,7.02] | 0.968 | |
Tumor subtype (RH/HER2) | RH+/HER2+ | 75 | 72(.96) | 36 | 35(.97) | 39 | 37(.95) | 0.53[0.05,6.05] | 0.612 | |
RH+/HER2- | 743 | 486(.65) | 332 | 218(.66) | 411 | 268(.65) | 0.98[0.72,1.33] | 0.897 | ||
RH-/HER2+ | 26 | 26(1.0) | <.001 | 15 | 15(1.0) | 11 | 11(1.0) | |||
RH-/HER2- | 45 | 44(.98) | 22 | 22(1.0) | 23 | 22(.96) | < 0.01[< 0.01,> 999.99] | 0.978 | ||
Harvested SN, number | =1 | 365 | 253(.69) | 165 | 115(.70) | 200 | 138(.69) | 0.97[0.62,1.51] | 0.886 | |
=2 | 303 | 205(.68) | 142 | 96(.68) | 161 | 109(.68) | 1.00[0.62,1.63] | 0.986 | ||
> 2 | 258 | 186(.72) | 0.519 | 116 | 86(.74) | 142 | 100(.70) | 0.83[0.48,1.44] | 0.509 | |
Involved SN | <=2 | 891 | 619(.69) | 406 | 285(.70) | 485 | 334(.69) | 0.94[0.71,1.25] | 0.668 | |
> 2 | 14 | 13(.93) | 0.059 | 6 | 6(1.0) | 8 | 7(.88) | < 0.01[< 0.01,> 999.99] | 0.979 | |
SN status | ITC | 56 | 31(.55) | <.001 | 22 | 14(.64) | 34 | 17(.50) | 0.58[0.19,1.71] | 0.322 |
Micro | 289 | 164(.57) | 133 | 76(.57) | 156 | 88(.56) | 0.97[0.61,1.55] | 0.900 | ||
Macro | 525 | 405(.77) | 241 | 183(.76) | 284 | 222(.78) | 1.13[0.75,1.71] | 0.544 | ||
Endocrine therapy | No | 75 | 66(.88) | <.001 | 29 | 28(.97) | 46 | 38(.83) | 0.17[0.02,1.45] | 0.106 |
Yes | 653 | 420(.64) | 302 | 192(.64) | 351 | 228(.65) | 1.06[0.77,1.46] | 0.714 | ||
Trastuzumab | No | 567 | 368(.65) | 256 | 162(.63) | 311 | 206(.66) | 1.14[0.81,1.61] | 0.463 | |
Yes | 83 | 83(1.0) | <.001 | 38 | 38(1.0) | 45 | 45(1.0) | |||
Breast Surgery | Mastectomy | 160 | 120(.75) | 0.099 | 73 | 55(.75) | 87 | 65(.75) | 0.97[0.47,1.98] | 0.927 |
Conservative | 766 | 524(.68) | 350 | 242(.69) | 416 | 282(.68) | 0.94[0.69,1.28] | 0.688 | ||
Radiotherapy | No | 38 | 19(.50) | 0.010 | 19 | 10(.53) | 19 | 9(.47) | 0.81[0.23,2.86] | 0.749 |
Yes | 867 | 604(.70) | 390 | 273(.70) | 477 | 331(.69) | 0.97[0.73,1.30] | 0.846 |